Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays

Hepatology

Volumn 32, Issue 4 I, 2000, Pages 818-823

  Sarrazin, Christoph ^a   Teuber, Gerlinde ^a   Kokka, Robert ^b   Rabenau, Holger ^a   Zeuzem, Stefan ^a  

^a GOETHE UNIVERSITY   (Germany)

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS RNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GENE AMPLIFICATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; SERUM; VIREMIA; VIRUS DETECTION;

EID: 0033802570     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.17709     Document Type: Article

References (36)

1. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team
2. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma
3. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
4. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
5. Treatment of chronic hepatitis C: Comparative virologic response rates among the different interferons
6. Consensus interferon: A novel interferon for the treatment of hepatitis C
7. Therapy of hepatitis C: Interferon alfa-2a trials
8. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
9. Therapy of hepatitis C: Consensus interferon trials. Consensus Interferon Study Group
10. Therapy of hepatitis C: Interferon alfa-n1 trials
11. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C
12. Therapy of hepatitis C: Alpha interferon and ribavirin
13. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C
14. Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets
15. Replication of hepatitis C virus in B lymphocytes (CD19+)
16. Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy
17. Hepatic expression of hepatitis C virus RNA in chronic hepatitis C: A study by in situ reverse-transcription polymerase chain reaction
18. Quantitation of hepatitis C viral RNA in liver and serum samples using competitive polymerase chain reaction
19. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: Evidence of active replication in monocytes/macrophages and lymphocytes
20. Evaluation of hepatic HCV RNA before and after treatment with interferon alfa 2b or combined with ribavirin in chronic hepatitis
21. New perspectives in the diagnosis of hepatitis C
22. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
23. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay
24. Clinical evaluation of a new polymerase chain reaction assay (Amplicor HCV) for detection of hepatitis C virus
25. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant
26. Clinical laboratory evaluation of a new sensitive and specific assay for qualitative detection of hepatitis C virus RNA in clinical specimens
27. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology
28. Clinical application of the Quantiflex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA
29. Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin
30. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa
31. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT
32. Early predictors of response to treatment in patients with chronic hepatitis C
33. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group
34. Ultracentrifugation and concentration of a large volume of serum for HCV RNA during treatment may predict sustained and relapse response in chronic HCV infection
35. Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells
36. Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA